Asked whether U.S. regulators might change their minds about guidance on the regulatory path for bempedoic acid to lower low-density lipoprotein C (LDL-C), Esperion Therapeutics Inc. CEO Tim Mayleben said “the answer is that we don’t know. We know what we know today. That’s probably a question better addressed to the FDA and what they’re planning.”